Mn Services Vermogensbeheer B.V. Grows Stock Position in Cencora, Inc. $COR

Posted by Stanley Muller on Oct 9th, 2026

Mn Services Vermogensbeheer B.V. raised its position in shares of Cencora, Inc. (NYSE:COR – Free Report) by 81.4% during the 3rd quarter, Holdings Channel reports. The fund owned 97,524 shares of the company’s stock after purchasing an additional 43,752 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Cencora were worth $29,282,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. bought a new stake in Cencora in the second quarter worth $5,154,136,000. T. Rowe Price Investment Management Inc. raised its stake in Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares in the last quarter. Bank of America Corp DE lifted its position in Cencora by 6.9% during the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock valued at $1,300,033,000 after purchasing an additional 267,318 shares during the last quarter. Amundi lifted its position in Cencora by 43.5% during the second quarter. Amundi now owns 2,229,326 shares of the company’s stock valued at $630,855,000 after purchasing an additional 676,066 shares during the last quarter. Finally, Carmignac Gestion grew its stake in shares of Cencora by 58.7% in the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock worth $494,463,000 after buying an additional 646,112 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

COR opened at $321.16 on Friday. The business has a fifty day moving average of $318.25 and a 200 day moving average of $302.71. The stock has a market cap of $61.29 billion, a P/E ratio of 23.86, a PEG ratio of 1.63 and a beta of 0.58. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:COR – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The business had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. During the same quarter last year, the firm posted $4.00 earnings per share. The business’s revenue was up 5.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Cencora, Inc. will post 17.87 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Friday, August 14th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora’s dividend payout ratio (DPR) is currently 17.83%.

Analyst Ratings Changes

A number of analysts have recently weighed in on COR shares. Evercore restated an “outperform” rating and issued a $350.00 target price on shares of Cencora in a report on Thursday, August 6th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Bank of America lifted their price target on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 24th. Wells Fargo & Company boosted their price objective on Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $330.00 price objective on shares of Cencora in a research report on Tuesday, September 8th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $372.07.

Check Out Our Latest Analysis on Cencora

Insider Buying and Selling

In related news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. This trade represents a 36.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.38% of the stock is owned by corporate insiders.

Cencora Profile

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.